Loading…
← CockpitCompetitor Analysis › 9989.T Sundrug Co., Ltd.Open in the cockpit ↗

Sundrug Co., Ltd.9989.TCompetitor analysis, valuation and peers

Japan · JPY·Consumer Staples›Drugstore Chains

Japanese drugstore chain selling over-the-counter medicines, cosmetics and daily goods across the country.

≈ A Japanese CVS/WalgreensMomentum leader 87
Mkt cap
$3.07B
US dollars, full cap
Free float
57%
of shares outstanding
$/day
$16.5M
20-day average traded
Fwd P/E
14.9×
forward earnings
ROIC−WACC
+7.1 pp
WACC 5.0%
Hurdle
-13 pp
Req g minus delivered
Next earnings
91 days
17 Feb 2027
Close · JPY¥4,152
1D-1.5%
1W+7.9%
1M+13.6%
3M+10.8%
6M+10.4%
YTD-3.6%
1Y-0.7%
ATR %2.3%
52w lowhigh7.0% off high

What Sundrug does

Japanese drugstore chain selling over-the-counter medicines, cosmetics and daily goods across the country.

Earns the mark-up between buying and shelf prices on a wide range of low-priced goods, where food and daily necessities draw traffic to stores that also carry medicines and cosmetics. In-store dispensing adds prescription income, paid largely through Japan's public health insurance.

In one line: A Japanese CVS/Walgreens.

Products and services

  • Drugstore retail (OTC drugs, cosmetics)
  • Daily necessities retail

Customers

  • Retail consumers across Japan

Where it sits in the supply chain

  • Consumer Staples
  • Retail pharmacy
  • Drugstore chain retail

What could go right

  • Store consolidation/M&A in drugstore sector
  • Inbound tourist cosmetics purchases

What could go wrong

  • Intense price competition among drugstores
  • Regulatory drug-pricing pressure

Moat: narrow (scale, distribution). Large nationwide drugstore network scale in a consolidating Japanese retail-pharmacy industry.

Headquarters: Tokyo, Japan · Founded: 1958 · Employees: 7,457

Named competitors

Sundrug at a glance

Size Sundrug (9989.T) is a Japan Consumer Staples company (Drugstore Chains) with a market value of $3.07B, the 360th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥4,152 on 18 Nov 2026.

Performance Over six months the shares gained 10.4%, against +10.1% for the median peer and -1.4% for the Japan market (cap-weighted) — 6th highest of 12 in its peer set.

Growth Revenue grew 4.0% over the last twelve months (peer median +7.1%); the operating margin is 5.6% (peer median 4.8%).

Valuation It trades at 14.9× forward earnings against a peer median of 17.6× (2nd cheapest of 11).

Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -13 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 7.1 points above its cost of capital (5.0% WACC).

Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).

Relative performance

10011021 May 202621 Aug 202618 Nov 2026Peer median 1169989.T 111
Six months, rebased to 100: Sundrug against the median of its 11 peers (local-currency closes).

Sundrug financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥858B¥843B¥802B¥752B¥690B
Revenue growth—+5%+7%+9%—
Gross profit¥222B¥197B¥187B¥189B¥172B
EBITDA¥67.2B¥65.7B¥61.9B¥56.2B¥49.5B
Net income¥31.6B¥31.4B¥30.8B¥29.1B¥25.7B
Free cash flown/a¥13.0B¥7.71B¥4.76B¥12.6B
Capital expendituren/a¥31.1B¥34.3B¥38.2B¥26.1B
Total debt¥46.7B¥49.0B¥39.5B¥35.9B¥939M

Quarterly statements and history in the cockpit →

Sundrug competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%0%+5%+10%+15%GRDN76496032336039396038833391314830889627002727MEDPLUS9989.T6-month return →1-month return →
Up and to the right = strong over both horizons. Sundrug is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%20×30×GRDN7649603233603883339130889627MEDPLUS9989.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sundrug is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%0%20%GRDN76496032336038833391314830889627002727MEDPLUS9989.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sundrug is the large dot.

Sundrug competitors and peer comparison

Head to head with its named competitors (9989.T vs 7649.T vs 9627.T vs 3349.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Sundrug 9989.T$3.07B+10%+4%6%14.9×-7.3%
Sugi 7649.T$3.46B-9%+9%5%17.9×-9.0%
Ain 9627.T$1.25B+2%+42%4%13.8×-6.5%
COSMOS Pharmaceutical 3349.T$3.21B+2%+9%4%15.9×n/a

How Sundrug compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sundrug against its 11 peers (data as of 18 Nov 2026)
Measure9989.TPeer medianRank in peer set
1-month return+13.6%+4.1%3rd highest of 12
6-month return+10.4%+10.1%6th highest of 12
Distance from 52-week high-7.0%-8.9%6th highest of 12
Revenue growth (TTM)+4.0%+7.1%3rd lowest of 12
Operating margin5.6%4.8%5th highest of 12
Forward P/E14.9×17.6×2nd cheapest of 11
Growth the price implies (Req g, 7 yrs)-7.3%-9.0%6th most demanding of 12
Growth delivered (Del g)+5.8%+13.2%lowest of 12
Hurdle (Req g minus delivered)-13.2 pp-20.3 pp4th most demanding of 12
ROIC minus cost of capital+7.1 pp+8.0 pp6th lowest of 12
EV / EBITDA7.0×8.6×3rd cheapest of 8
Net debt / EBITDA-0.3×-0.4×4th most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Sundrug 9989.TJapan$3.07B+10%+4%6%14.9×-7.3%+5.8%
Guardian Pharmacy Services GRDNUnited States$3.09B+30%+5%6%33.3×4.4%+16.8%
Sugi 7649.TJapan$3.46B-9%+9%5%17.9×-9.0%+10.9%
DaShenLin Pharmaceutical 603233.SSChina$3.64B+10%+7%8%15.9×-9.5%+13.6%
Yifeng Pharmacy Chain 603939.SSChina$4.84B+16%+5%10%17.2×-9.3%+13.2%
LBX Pharmacy Chain Joint Stock 603883.SSChina$1.71B+13%+3%5%16.1×-10.7%+9.7%
TSURUHA 3391.TJapan$7.15B+17%+114%4%23.8×-1.5%+9.6%
Create SD 3148.TJapan$1.32B+3%+9%5%n/a-11.5%+8.0%
MatsukiyoCocokara & 3088.TJapan$7.51B+29%+6%8%19.5×-4.8%+15.5%
Ain 9627.TJapan$1.25B+2%+42%4%13.8×-6.5%+16.9%
Yixintang Pharmaceutical 002727.SZChina$1.16B+4%-2%3%16.6×-16.0%+6.5%
MedPlus Health Services MEDPLUS.NSIndia$771M-36%+21%4%33.9×18.6%+17.6%

Questions

Who are Sundrug's main competitors?
Named competitors: Sugi Holdings (7649.T), Ain Holdings (9627.T), Cosmos Pharmaceutical (3349.T), Welcia Holdings (private or unlisted). The cockpit's measured peer set (industry) also includes Guardian Pharmacy Services (GRDN), Sugi (7649.T), DaShenLin Pharmaceutical (603233.SS), Yifeng Pharmacy Chain (603939.SS), LBX Pharmacy Chain Joint Stock (603883.SS), TSURUHA (3391.T).
Is Sundrug expensive compared with its peers?
On forward p/e it trades at 14.9× against a peer median of 17.6×, 2nd cheapest of 11 in its peer set. For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -13 pp: the price already allows for a slowdown.
How has Sundrug stock performed?
Over six months to 18 Nov 2026 the shares returned +10.4% against +10.1% for the median peer; over one year -0.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.